Streetwise Articles


Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

Contributed Opinion
  ()
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. read more >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Research Report
  ()
An Echelon Wealth Partners report discussed the deal terms. read more >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

Research Report
  ()
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications. read more >

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device

Research Report
  ()
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. read more >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

Research Report
  ()
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. read more >
News Update

Drug Company Receives $5 Million Milestone Payment

News Update
  ()
Company entitled to receive quarterly earn-out payments from patent agreement. read more >

Oncology-Focused Biotech Receives Orphan Status for AML Drug

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. read more >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News

Research Report
  ()
An analyst discussed the implications to this firm of a competitive product's advancement. read more >
News Update

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment

News Update
  ()
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. read more >

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment

Research Report
  ()
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. read more >
News Update

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible

  ()
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. read more >
News Update

Biosciences Company Announces Research Collaboration for Testing Cannabis Ingredients

News Update
  ()
The development of analytic methods is a key milestone in the development of water-soluble cannabis technology. read more >

Biotech Marks Progress on Programs for Cancer, Infectious Diseases

Research Report
  ()
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. read more >

Medical Device Firm's Clinical Programs Progress in Q2/18

Research Report
  ()
A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence. read more >

Medical Device Firm Anticipates Benefit from Patent Ruling

  ()
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent. read more >

Biopharma Signs Multimillion-Dollar Deal for Key Products in China

Research Report
  ()
An H.C. Wainwright & Co. report reviewed the arrangement. read more >
News Update

U.S. Medical Device Firm Pursues ISO 13485 Certification

News Update
  ()
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system. read more >

Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug

Research Report
  ()
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts. read more >

Biotech Releases White Paper on Alzheimer's Disease Candidate

  ()
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate. read more >

Interim Readout for Pharma Trial 'Delivers Home Run'

Research Report
  ()
An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections. read more >

Health Technology Stock 'Set to Break Higher'

Contributed Opinion
  ()
Technical analyst Clive Maund charts a health technology stock whose platform allows hospitals and healthcare organizations to buy, sell and trade surplus medical equipment and supplies. read more >

Biopharma Releases New Antibiotic in the US for Complicated UTIs

Research Report
  ()
A LifeSci Capital report reviewed why uptake of a drug that targets complicated urinary tract infections could be significant and swift. read more >

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'

Research Report
  ()
A Maxim Group report reviewed the deal between the two companies. read more >
News Update

Healthcare Tech Company Receives US Patent

News Update
  ()
The U.S Patent and Trademark Office has granted the allowance to a technology company whose platform allows healthcare organizations to buy, sell and trade equipment and supplies. read more >

Cannabis Firm Targets Sexual Health and Wellness

Contributed Opinion
  ()
California, with nearly 40 million residents, offers a cannabis market as large as the whole of Canada, says Ron Struthers, editor of Struthers Resource Stock Report. He believes that companies that have a road into California will gain early traction, and he profiles one such firm. read more >
Showing Results: 1 to 25 of 66 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"PMN anticipates launching its first in-human trial in 2019 of PMN310." ❭
– John Vandermosten, Zacks Small-Cap Research